CXCR4 antagonist
Motixafortide
Answer
Motixafortide is authorised or registered in the US and Singapore: 2 of the 10 registers read. Highest trial phase: Phase 3 (1 phase 3 trial, 0 with posted results). It has 11 registered trials, 6 of them running. Brand names on the FDA label register: Aphexda.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
11 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 1 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 6 years · read 2026-10-03. 2026 is not complete. 1 trial carries no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Not on the register | EMA, ema | 2026-08-31 |
| United Kingdom | Not on the register | MHRA, uk-mhra | 2026-09-03 |
| Canada | Not on the register | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Not on the register | Swissmedic, ch-swissmedic | 2026-09-03 |
| Brazil | Not on the register | ANVISA, br-anvisa | 2026-09-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Not on the register | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Motixafortide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 11 trials
| NCT04543071 | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma running, but no longer enrolling · register updated 2026-09-21 |
|---|---|
| NCT06514508 | Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients currently recruiting participants · register updated 2026-09-14 |
| NCT06442761 | SCD Stem Cell Mobilization and Apheresis Using Motixafortide currently recruiting participants · register updated 2026-09-08 |
| 2024-511953-23-00 | A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy o no status recorded · register updated 2026-07-29 |
| NCT07392970 | Motixafortide for MRD Sensitization in AML currently recruiting participants · register updated 2026-07-24 |
| NCT07101445 | Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Re currently recruiting participants · register updated 2026-07-23 |
| NCT06506461 | Gene Editing For Sickle Cell Disease currently recruiting participants · register updated 2026-05-05 |
| NCT06547112 | A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide completed · register updated 2025-08-29 |
| NCT05618301 | Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) completed · register updated 2025-08-11 |
| NCT05293171 | Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects completed · register updated 2025-03-21 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.